These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 29848706)

  • 1. Fisetin Enhances the Cytotoxicity of Gemcitabine by Down-regulating ERK-MYC in MiaPaca-2 Human Pancreatic Cancer Cells.
    Kim N; Kang MJ; Lee SH; Son JH; Lee JE; Paik WH; Ryu JK; Kim YT
    Anticancer Res; 2018 Jun; 38(6):3527-3533. PubMed ID: 29848706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fisetin Reduces Cell Viability Through Up-Regulation of Phosphorylation of ERK1/2 in Cholangiocarcinoma Cells.
    Kim N; Lee SH; Son JH; Lee JM; Kang MJ; Kim BH; Lee JS; Ryu JK; Kim YT
    Anticancer Res; 2016 Nov; 36(11):6109-6116. PubMed ID: 27793939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergy of gemcitabine and lidamycin associated with NF-kappaB downregulation in pancreatic carcinoma cells.
    Chen J; Wu SY; Ou-Yang ZG; Zhen YS
    Acta Pharmacol Sin; 2008 May; 29(5):614-9. PubMed ID: 18430374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mucin production determines sensitivity to bortezomib and gemcitabine in pancreatic cancer cells.
    Wissniowski TT; Meister S; Hahn EG; Kalden JR; Voll R; Ocker M
    Int J Oncol; 2012 May; 40(5):1581-9. PubMed ID: 22266985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting X-linked inhibitor of apoptosis protein inhibits pancreatic cancer cell growth through p-Akt depletion.
    Jiang C; Yi XP; Shen H; Li YX
    World J Gastroenterol; 2012 Jun; 18(23):2956-65. PubMed ID: 22736919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiprotease strategy in pancreatic cancer treatment: emergence from a preclinical study.
    Brandi G; Tavolari S; Guarnieri T; Di Marco M; Paterini P; Macchini M; Di Girolamo S; Papi A; De Rosa F; Biasco G
    Pancreas; 2014 Jan; 43(1):53-63. PubMed ID: 24201777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amphiregulin regulates the activation of ERK and Akt through epidermal growth factor receptor and HER3 signals involved in the progression of pancreatic cancer.
    Yotsumoto F; Fukami T; Yagi H; Funakoshi A; Yoshizato T; Kuroki M; Miyamoto S
    Cancer Sci; 2010 Nov; 101(11):2351-60. PubMed ID: 20726858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Natural Flavonoid Fisetin Inhibits Cellular Proliferation of Hepatic, Colorectal, and Pancreatic Cancer Cells through Modulation of Multiple Signaling Pathways.
    Youns M; Abdel Halim Hegazy W
    PLoS One; 2017; 12(1):e0169335. PubMed ID: 28052097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II.
    Awasthi N; Zhang C; Hinz S; Schwarz MA; Schwarz RE
    J Exp Clin Cancer Res; 2013 Mar; 32(1):12. PubMed ID: 23497499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition.
    Waters AM; Khatib TO; Papke B; Goodwin CM; Hobbs GA; Diehl JN; Yang R; Edwards AC; Walsh KH; Sulahian R; McFarland JM; Kapner KS; Gilbert TSK; Stalnecker CA; Javaid S; Barkovskaya A; Grover KR; Hibshman PS; Blake DR; Schaefer A; Nowak KM; Klomp JE; Hayes TK; Kassner M; Tang N; Tanaseichuk O; Chen K; Zhou Y; Kalkat M; Herring LE; Graves LM; Penn LZ; Yin HH; Aguirre AJ; Hahn WC; Cox AD; Der CJ
    Cell Rep; 2021 Jun; 35(13):109291. PubMed ID: 34192548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitogen-activated protein kinases and chemoresistance in pancreatic cancer cells.
    Zhao Y; Shen S; Guo J; Chen H; Greenblatt DY; Kleeff J; Liao Q; Chen G; Friess H; Leung PS
    J Surg Res; 2006 Dec; 136(2):325-35. PubMed ID: 17054996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
    Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW
    Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of AKT2 enhances sensitivity to gemcitabine via regulating PUMA and NF-κB signaling pathway in human pancreatic ductal adenocarcinoma.
    Chen D; Niu M; Jiao X; Zhang K; Liang J; Zhang D
    Int J Mol Sci; 2012; 13(1):1186-1208. PubMed ID: 22312312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of c-Myc and RRM2 expression in pancreatic cancer cells by the sphingosine kinase-2 inhibitor ABC294640.
    Lewis CS; Voelkel-Johnson C; Smith CD
    Oncotarget; 2016 Sep; 7(37):60181-60192. PubMed ID: 27517489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells.
    Bocci G; Fioravanti A; Orlandi P; Bernardini N; Collecchi P; Del Tacca M; Danesi R
    Br J Cancer; 2005 Aug; 93(3):319-30. PubMed ID: 16052215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced effect of gemcitabine by emodin against pancreatic cancer in vivo via cytochrome C-regulated apoptosis.
    Chen H; Wei W; Guo Y; Liu A; Tong H; Wang Z; Tan W; Liu J; Lin S
    Oncol Rep; 2011 May; 25(5):1253-61. PubMed ID: 21305255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of c-Myc down-regulation by sustained extracellular signal-regulated kinase activation prevents the antimetabolite methotrexate- and gemcitabine-induced differentiation in non-small-cell lung cancer cells.
    Serra JM; Gutiérrez A; Alemany R; Navarro M; Ros T; Saus C; Ginés J; Sampol A; Amat JC; Serra-Moisés L; Martín J; Galmés A; Vögler O; Besalduch J
    Mol Pharmacol; 2008 Jun; 73(6):1679-87. PubMed ID: 18353995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dickkopf3 overexpression inhibits pancreatic cancer cell growth in vitro.
    Gu YM; Ma YH; Zhao WG; Chen J
    World J Gastroenterol; 2011 Sep; 17(33):3810-7. PubMed ID: 21987623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Knockdown of clusterin sensitizes pancreatic cancer cells to gemcitabine chemotherapy by ERK1/2 inactivation.
    Tang Y; Liu F; Zheng C; Sun S; Jiang Y
    J Exp Clin Cancer Res; 2012 Sep; 31(1):73. PubMed ID: 22967941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic cytotoxicity and molecular interaction on drug targets of sorafenib and gemcitabine in human pancreas cancer cells.
    Ricciardi S; Mey V; Nannizzi S; Pasqualetti G; Crea F; Del Tacca M; Danesi R
    Chemotherapy; 2010; 56(4):303-12. PubMed ID: 20714148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.